Method and system for detecting and differentiating cancer and sepsis in mammals using biomarkers

A method for diagnosing cancer in canine subjects comprising the steps of:

• a) obtaining a blood serum sample from a canine subject;
• b) obtaining the enzymatic level of thymidine kinase in the blood serum sample and
• assigning a discrete value of zero (0) to said thymidine level when the thymidine level is less than 1.7 U/l;
• assigning a discrete value of one (1) to said thymidine level when the thymidine level is between 1.8 U/l and 4 U/l;
• assigning a discrete value of two (2) to said thymidine level when the thymidine level is between 4.1 U/l and 7 U/l;
• or
• assigning a discrete value of three (3) to said thymidine level, when the thymidine level is greater than about 7.1 U/l;
• c) obtaining a concentration of c-reactive protein in said blood serum sample and
• assigning a discrete value of zero (0) to said c-reactive protein concentration when the c-reactive protein concentration is less than 3.9 mg/l;
• assigning a discrete value of one (1) to said c-reactive protein concentration when the c-reactive protein concentration is between 4 mg/l and 9.5 mg/l;
• or
• assigning a discrete value of two (2) to said c-reactive protein concentration, when the c-reactive protein concentration is greater than 9.5 mg/l;
• and
• d) computing an index value by adding:
• the thymidine kinase discrete value multiplied by a thymidine kinase weighing coefficient of value 1.7, and
• the c-reactive protein discrete value multiplied by a c-reactive protein weighing coefficient of 2.32;
• wherein the canine subject is a carrier of cancer if said index value is above a criterion value of 1.0.

A method for detecting cancer in canine subjects comprising the steps of:

• a) obtaining a blood serum sample from a canine subject;
• b) obtaining the enzymatic level of thymidine kinase in the blood serum sample and
• assigning a discrete value of zero (0) to said thymidine level when the thymidine level than 17 U/l;
• assigning a discrete value of one (1) to said thymidine level when the thymidine level is between 1.8 U/l and 4 U/l;
• assigning a discrete value of two (2) to said thymidine level when the thymidine level is between 4.1 U/l and 7 U/l;
• or
• assigning a discrete value of three (3) to said thymidine level, when the thymidine level is greater than about 7.1 U/l;
• c) obtaining a concentration of c-reactive protein in said blood serum sample and
• assigning a discrete value of zero (0) to said c-reactive protein concentration when the c-reactive protein concentration is less than 3.9 mg/l;
• assigning a discrete value of one (1) to said c-reactive protein concentration when the c-reactive protein concentration is between 4 mg/l and 9.5 mg/l;
• or
• assigning a discrete value of two (2) to said c-reactive protein concentration, when the c-reactive protein concentration is greater than 9.5 mg/l;
• d) obtaining a concentration of C-type natriuretic peptide in said blood serum sample and
• assigning a discrete value of zero (0) to the concentration of C-type natriuretic peptide when the concentration of C-type natriuretic peptide is less than 3.8 picomole/l;
• assigning a discrete value of one (1) to the concentration of C-type natriuretic peptide when the concentration of C-type natriuretic peptide is between about 3.9 picomole/l and 11.4 picomole/l;
• or
• assigning a discrete value of two (2) to the concentration of C-type natriuretic peptide, when the concentration of C-type natriuretic peptide is greater than 11.5 picomole/l, and
• e) computing an index value by adding:
• the thymidine kinase discrete value multiplied by a thymidine kinase weighing coefficient of value 1.63, and
• the c-reactive protein discrete value multiplied by a c-reactive protein weighing coefficient of 2.18, and
• the C-type natriuretic peptide discrete value multiplied by a C-type natriuretic peptide weighing coefficient of 1.68;
• wherein the canine subject is a carrier of cancer if said index value is above a criterion value of 1.0.